Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus DILOR 400.
AEROLATE III vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator